Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline

Technical Details of Intraoperative Lymphatic Mapping for Early Stage Melanoma

Morton, D. L. (1992) · Archives of Surgery · doi:10.1001/archsurg.1992.01420040034005 · Cited by 4,371

Distinct Sets of Genetic Alterations in Melanoma

Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050092 · Cited by 2,747

Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma

Balch, C. M., Buzaid, A. C., Soong, S.-J., Atkins, M. B., Cascinelli, N., Coit, D. G., Fleming, I. D., Gershenwald, J. E., Houghton, A., Kirkwood, J. M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.16.3635 · Cited by 2,636

Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial

Andrews, D. W., Scott, C. B., Sperduto, P. W., Flanders, A. E., Gaspar, L. E., Schell, M. C., Werner-Wasik, M., Demas, W., Ryu, J., Bahary, J.-P., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16250-8 · Cited by 2,417

Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System

Balch, C. M., Soong, S.-J., Gershenwald, J. E., Thompson, J. F., Reintgen, D. S., Cascinelli, N., Urist, M., McMasters, K. M., Ross, M. I., Kirkwood, J. M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.16.3622 · Cited by 2,388

The histogenesis and biologic behavior of primary human malignant melanomas of the skin.

Clark, W. H., From, L., Bernardino, E. A., & Mihm, M. C. (1969) · PubMed · Cited by 2,112

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

Kirkwood, J. M., Strawderman, M. H., Ernstoff, M. S., Smith, T. J., Borden, E. C., & Blum, R. H. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.1.7 · Cited by 2,094

High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993

Atkins, M. B., Lotze, M. T., Dutcher, J. P., Fisher, R. I., Weiss, G., Margolin, K., Abrams, J., Sznol, M., Parkinson, D., Hawkins, M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2105 · Cited by 2,048

Postoperative Radiotherapy in the Treatment of Single Metastases to the Brain: A Randomized Trial

Patchell, R. A., Tibbs, P. A., Regine, W. F., Dempsey, R. J., Mohiuddin, M., Kryscio, R. J., Markesbery, W. R., Foon, K. A., & Young, B. (1998) · JAMA · doi:10.1001/jama.280.17.1485 · Cited by 1,915

Sentinel-Node Biopsy or Nodal Observation in Melanoma

Morton, D. L., Thompson, J. F., Cochran, A. J., Mozzillo, N., Elashoff, R., Essner, R., Nieweg, O. E., Roses, D. F., Hoekstra, H. J., Karakousis, C. P., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060992 · Cited by 1,824

Somatic Activation of KIT in Distinct Subtypes of Melanoma

Curtin, J. A., Busam, K., Pinkel, D., & Bastian, B. C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2984 · Cited by 1,616

Diagnostic accuracy of dermoscopy

Kittler, H., Pehamberger, H., Wolff, K., & Binder, M. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00679-4 · Cited by 1,349

Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma

Middleton, M. R., Grob, J. J., Aaronson, N., Fierlbeck, G., Tilgen, W., Seiter, S., Gore, M., Aamdal, S., Cebon, J., Coates, A., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.158 · Cited by 1,272

High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190

Kirkwood, J. M., Ibrahim, J. G., Sondak, V. K., Richards, J., Flaherty, L. E., Ernstoff, M. S., Smith, T. J., Rao, U., Steele, M., & Blum, R. H. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.12.2444 · Cited by 912

Management of Cutaneous Melanoma

Tsao, H., Atkins, M. B., & Sober, A. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041245 · Cited by 855

Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma

Chapman, P. B., Einhorn, L. H., Meyers, M. L., Saxman, S., Destro, A. N., Panageas, K. S., Begg, C. B., Agarwala, S. S., Schuchter, L. M., Ernstoff, M. S., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2745 · Cited by 764

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

Eggermont, A. M., Suciu, S., Santinami, M., Testori, A., Kruit, W. H., Marsden, J., Punt, C. J., Salès, F., Gore, M., MacKie, R., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61033-8 · Cited by 640

Number of melanocytic nevi as a major risk factor for malignant melanoma

Holly, E. A., Kelly, J. W., Shpall, S. N., & Chiu, S.-H. (1987) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(87)70230-8 · Cited by 503

The classification of malignant melanoma and its histologic reporting

McGovern, V. J., Mihm, M. C., Bailly, C., Booth, J. C., Clark, W. H., Cochran, A. J., Hardy, E. G., Hicks, J. D., Levene, A., Lewis, M. G., et al. (1973) · Cancer · doi:10.1002/1097-0142(197312)32:6<1446::aid-cncr2820320623>3.0.co;2-8 · Cited by 443

Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1·5 mm without clinically detectable node metastases

Grob, J. J., Dreno, B., de la Salmoniere, P., Delaunay, M., Cupissol, D., Guillot, B., Souteyrand, P., Sassolas, B., Cesarini, J.-P., Lionnet, S., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(97)12445-x · Cited by 433

Changing epidemiology of malignant cutaneous melanoma in Europe 1953–1997: Rising trends in incidence and mortality but recent stabilizations in Western Europe and decreases in Scandinavia

de Vries, E., Bray, F. I., Coebergh, J. W. W., Parkin, D. M., & European Network of Cancer Registries (2003) · International Journal of Cancer · doi:10.1002/ijc.11360 · Cited by 378

U.K. guidelines for the management of cutaneous melanoma

Roberts, D. L., Anstey, A. V., Barlow, R., Cox, N. H., Newton‐Bishop, J., Corrie, P. G., Evans, J., Gore, M. E., Hall, P. N., & Kirkham, N. (2002) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2001.04614.x · Cited by 324

Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials

Eigentler, T. K., Caroli, U. M., Radny, P., & Garbe, C. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01280-4 · Cited by 324

Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial

Eggermont, A. M., Suciu, S., MacKie, R., Ruka, W., Testori, A., Kruit, W., Punt, C. J., Delauney, M., Sales, F., Groenewegen, G., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67482-x · Cited by 311

Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study.

Falkson, C. I., Ibrahim, J., Kirkwood, J. M., Coates, A. S., Atkins, M. B., & Blum, R. H. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.5.1743 · Cited by 303

Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma.

Bleehen, N. M., Newlands, E. S., Lee, S. M., Thatcher, N., Selby, P., Calvert, A. H., Rustin, G. J., Brampton, M., & Stevens, M. F. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.4.910 · Cited by 282

Count of benign melanocytic nevi as a major indicator of risk for nonfamilial nodular and superficial spreading melanoma

Grob, J. J., Gouvernet, J., Aymar, D., Mostaque, A., Romano, M. H., Collet, A. M., Noe, M. C., Diconstanzo, M. P., & Bonerandi, J. J. (1990) · Cancer · doi:10.1002/1097-0142(19900715)66:2<387::aid-cncr2820660232>3.0.co;2-j · Cited by 259

Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial

Cascinelli, N., Belli, F., MacKie, R. M., Santinami, M., Bufalino, R., & Morabito, A. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06068-8 · Cited by 250

Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593.

Koops, H. S., Vaglini, M., Suciu, S., Kroon, B. B., Thompson, J. F., Göhl, J., Eggermont, A. M., Di Filippo, F., Krementz, E. T., Ruiter, D., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.9.2906 · Cited by 246

Neoadjuvant Treatment of Regional Stage IIIB Melanoma With High-Dose Interferon Alfa-2b Induces Objective Tumor Regression in Association With Modulation of Tumor Infiltrating Host Cellular Immune Responses

Moschos, S. J., Edington, H. D., Land, S. R., Rao, U. N., Jukic, D., Shipe-Spotloe, J., & Kirkwood, J. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.2498 · Cited by 242

Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology

Overgaard, J., Gonzalez, D. G., Hulshof, M. C. C. H., Arcangeli, G., Dahl, O., Mella, O., & Bentzen, S. M. (1996) · International Journal of Hyperthermia · doi:10.3109/02656739609023685 · Cited by 227

Diagnosis and treatment of cutaneous melanoma: state of the art 2006*

Garbe, C., & Eigentler, T. K. (2007) · Melanoma Research · doi:10.1097/cmr.0b013e328042bb36 · Cited by 223

Incidence of and survival from malignant melanoma in Scotland: an epidemiological study

MacKie, R. M., Bray, C. A., Hole, D. J., Morris, A., Nicolson, M., Evans, A., Doherty, V., & Vestey, J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09779-9 · Cited by 220

Acquired Melanocytic Nevi as Risk Factor for Melanoma Development. A Comprehensive Review of Epidemiological Data

Bauer, J., & Garbe, C. (2003) · Pigment Cell Research · doi:10.1034/j.1600-0749.2003.00047.x · Cited by 209

Epidemiology of Cutaneous Melanoma in Germany and Worldwide

Garbe, C., & Blum, A. (2001) · Skin Pharmacology and Physiology · doi:10.1159/000056358 · Cited by 209

Associated Factors in the Prevalence of More Than 50 Common Melanocytic Nevi, Atypical Melanocytic Nevi, and Actinic Lentigines: Multicenter Case-Control Study of the Central Malignant Melanoma Registry of the German Dermatolgocial Society

Garbe, C., Krüger, S., Orfanos, C. E., Büttner, P., Weiß, J., Soyer, H. P., Stocker, U., Roser, M., Weckbecker, J., Panizzon, R., et al. (1994) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12374298 · Cited by 183

The Clinical Diagnosis, Classification and Histogenetic Concepts of the Early Stages of Cutaneous Malignant Melanomas

Mihm, M. C., Clark, W. H., & From, L. (1971) · New England Journal of Medicine · doi:10.1056/nejm197105132841907 · Cited by 162

Primary staging and follow-up in melanoma patients – monocenter evaluation of methods, costs and patient survival

Hofmann, U., Szedlak, M., Rittgen, W., Jung, E. G., & Schadendorf, D. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600428 · Cited by 159

Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma.

Bajetta, E., Leo, A. D., Zampino, M. G., Sertoli, M. R., Comella, G., Barduagni, M., Giannotti, B., Queirolo, P., Tribbia, G., & Bernengo, M. G. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.4.806 · Cited by 152

Adjuvant low-dose interferon α2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis

Garbe, C., Radny, P., Linse, R., Dummer, R., Gutzmer, R., Ulrich, J., Stadler, R., Weichenthal, M., Eigentler, T., Ellwanger, U., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn001 · Cited by 138

Practical guidelines for the management of interferon‐α‐2b side effects in patients receiving adjuvant treatment for melanoma: Expert opinion

Hauschild, A., Gogas, H. J., Tarhini, A. A., Middleton, M. R., Testori, A., Dréno, B., & Kirkwood, J. M. (2008) · Cancer · doi:10.1002/cncr.23251 · Cited by 130

Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma

Garbe, C., Hauschild, A., Volkenandt, M., Schadendorf, D., Stolz, W., Reinhold, U., Kortmann, R., Kettelhack, C., Frerich, B., Keilholz, U., et al. (2007) · Melanoma Research · doi:10.1097/cmr.0b013e3282f05039 · Cited by 129

Combination of paclitaxel and carboplatin as second‐line therapy for patients with metastatic melanoma

Rao, R. D., Holtan, S. G., Ingle, J. N., Croghan, G. A., Kottschade, L. A., Creagan, E. T., Kaur, J. S., Pitot, H. C., & Markovic, S. N. (2005) · Cancer · doi:10.1002/cncr.21611 · Cited by 124

EORTC Melanoma Group. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.

Am, E., Suciu, S., Santinami, M., Testori, A., Kruit, W. H. J., Marsden, J. R., Punt, C. J. A., Salès, F., Gore, M. E., MacKie, R., et al. (2008) · Research Explorer (The University of Manchester) · Cited by 111

Surveillance of patients at high risk for cutaneous malignant melanoma using digital dermoscopy

Bauer, J. M., Blum, A., Strohhäcker, U., & Garbe, C. (2005) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2005.06370.x · Cited by 103

Gamma-Knife radiosurgery in the management of melanoma patients with brain metastases: A series of 106 patients without whole-brain radiotherapy

Gaudy‐Marqueste, C., Régis, J.-M., Muracciole, X., Laurans, R., Richard, M. A., Bonerandi, J. J., & Grob, J. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2006.01.024 · Cited by 97

Short German guidelines: Malignant melanoma

Garbe, C., Schadendorf, D., Stolz, W., et al. (2008) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/j.1610-0387.2008.06711.x · Cited by 94

Evidence and interdisciplinary consensus-based German guidelines: surgical treatment and radiotherapy of melanoma

Garbe, C., Hauschild, A., Volkenandt, M., et al. (2008) · Melanoma Research · doi:10.1097/cmr.0b013e3282f0c893 · Cited by 91

Interobserver reproducibility of ulceration assessment in primary cutaneous melanomas

Spatz, A., Cook, M. G., Elder, D. E., et al. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00325-3 · Cited by 88

Cutaneous malignant melanoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

Dummer, R., Hauschild, A., & Pentheroudakis, G. E. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp152 · Cited by 86

Lentigo Maligna

Stevenson, O., & Ahmed, I. (2005) · American Journal of Clinical Dermatology · doi:10.2165/00128071-200506030-00002 · Cited by 85

Trends in Incidence of Cutaneous Malignant Melanoma in a Swedish Population 1976-1994

Månsson‐Brahme, E., Johansson, H., Larsson, O., Rutqvist, L. E., & Ringborg, U. K. (2002) · Acta Oncologica · doi:10.1080/028418602753669508 · Cited by 82

Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting

Garbe, C., Hauschild, A., Volkenandt, M., Schadendorf, D., Stolz, W., Reinhold, U., Kortmann, R., Kettelhack, C., Frerich, B., Keilholz, U., et al. (2008) · Melanoma Research · doi:10.1097/cmr.0b013e3282f702bf · Cited by 71

Management of familial melanoma

Newton‐Bishop, J., Harland, M., Randerson‐Moor, J. A., & Bishop, D. T. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)71010-5 · Cited by 69

Prospective Randomized Comparison of Dacarbazine (DTIC) Versus DTIC Plus Interferon-Alpha (IFN-α) in Metastatic Melanoma

Young, A. M., Marsden, J. R., Goodman, A. G., et al. (2001) · Clinical Oncology · doi:10.1053/clon.2001.9314 · Cited by 64

Cutaneous melanoma: methods of biopsy and definitive surgical excision

Riker, A. I., Glass, F., Pérez, I. R., Cruse, C. W., Messina, J. L., & Sondak, V. K. (2005) · Dermatologic Therapy · doi:10.1111/j.1529-8019.2005.00045.x · Cited by 38

Randomized trial of recombinant alpha 2b-interferon with or without indomethacin in patients with metastatic malignant melanoma.

Miller, R. L., Steis, R. G., Clark, J. W., Smith, J. W., Crum, E. D., McKnight, J. E., Hawkins, M., Jones, M. J., Longo, D., & Urba, W. J. (1989) · PubMed · Cited by 38

From sporadic atypical nevi to familial melanoma: Risk analysis for melanoma in sporadic atypical nevus patients

de Snoo, F. A., Kroon, M. W., Bergman, W., ter Huurne, J., Houwing‐Duistermaat, J. J., van Mourik, L., Snels, D. G. C. T. M., Breuning, M. H., Willemze, R., Frants, R. R., et al. (2007) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2007.01.010 · Cited by 34

Adjuvant Therapy of Melanoma

Shah, G., & Chapman, P. B. (2007) · The Cancer Journal · doi:10.1097/ppo.0b013e318074dfd4 · Cited by 27

Direct Effects of Type I Interferons on Cells of the Immune System

Hervas-Stubbs, S., Perez-Gracia, J. L., Rouzaut, A., Sanmamed, M. F., Le Bon, A., & Melero, I. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1114 · Cited by 503

Malignant melanoma cells acquire resistance to DNA interstrand cross-linking chemotherapeutics by p53-triggered upregulation of DDB2/XPC-mediated DNA repair

Barckhausen, C., Roos, W. P., Naumann, S. C., & Kaina, B. (2014) · Oncogene · doi:10.1038/onc.2013.141 · Cited by 77